Catalent will buy Cook Pharmica for $950 million in cash, giving the company access to Cook Pharmica’s Bloomington, Indiana facility that specializes in biologics-based drug development. Currently, biologics account for nearly 14 percent of Catalent’s consolidated revenue.
Catalent is expected to pay $750 million at deal closes in the second quarter of the 2018 fiscal year.
Last year, Cook Pharmica generated $179 million in revenue.
Read the Reuters report